Today: 21 May 2026
Browse Category

BMV:VOLAR 20 December 2025 - 21 December 2025

Mexico Stock Exchange Update (Dec. 21, 2025): IPC Near Record High After Banxico Rate Cut, Volaris Rally, and 2026 Targets of 69,200–71,000

Mexico Stock Exchange Update (Dec. 21, 2025): IPC Near Record High After Banxico Rate Cut, Volaris Rally, and 2026 Targets of 69,200–71,000

Mexico’s S&P/BMV IPC index closed Friday at 63,966.98, just below its record high set earlier in December. The index is up about 29% for 2025 despite a 1.15% weekly drop. Banco de México cut its key rate by 25 basis points to 7.00% on Dec. 19, citing weak economic activity and rising inflation. Trading volume reached 745.5 million shares, worth 49.7 billion pesos.
21 December 2025
·
Mexico Stock Exchange News (Dec. 20, 2025): BMV Holds Near 64,000 as Banxico Cuts to 7%, Volaris-Viva Merger Sparks Rally, and 2026 IPC Forecasts Firm Up

Mexico Stock Exchange News (Dec. 20, 2025): BMV Holds Near 64,000 as Banxico Cuts to 7%, Volaris-Viva Merger Sparks Rally, and 2026 IPC Forecasts Firm Up

Mexico’s S&P/BMV IPC closed Friday at 63,966.98, up 0.25% for the day but down 1.15% for the week, marking its second weekly decline in three weeks. Volaris surged after news of a planned merger with Viva Aerobus, while Televisa and TEAK fell sharply. The index remains up for December and on track for one of its strongest years in over a decade.
20 December 2025
·

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop